UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000022974
Receipt No. R000026301
Scientific Title Effects of a Food Containing Mushroom Mycelium Powder on Temporal or Long-Term Fatigue by Physical Labour, Quality of Sleep, and Vitality.
Date of disclosure of the study information 2016/07/01
Last modified on 2017/02/09

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Effects of a Food Containing Mushroom Mycelium Powder on Temporal or Long-Term Fatigue by Physical Labour, Quality of Sleep, and Vitality.
Acronym Effects of a Food Containing Mushroom Mycelium Powder on Temporal or Long-Term Fatigue by Physical Labour, Quality of Sleep, and Vitality.
Scientific Title Effects of a Food Containing Mushroom Mycelium Powder on Temporal or Long-Term Fatigue by Physical Labour, Quality of Sleep, and Vitality.
Scientific Title:Acronym Effects of a Food Containing Mushroom Mycelium Powder on Temporal or Long-Term Fatigue by Physical Labour, Quality of Sleep, and Vitality.
Region
Japan

Condition
Condition Healthy adults feeling tired by work
Classification by specialty
Adult
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 This study examines effects of a food containing mushroom mycelium powder on temporal of long-term fatigue by physical labour, quality of sleep, and vitality.
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes [Fatigue and vitality]
(1)CFS (Chalder's Fatigue Scale) (Week 0, 1, 4, 8, 12)
(2)Japanese Edition of Profile of Mood States (Week 0, 1, 4, 8, 12)
[Sleep]
(1)Pittsburgh Sleep Quality Index, Japanese Version (Week 0, 4, 8, 12)
(2)Obstructive Sleep Apnea Questionnaire (Week 0, 1)
Key secondary outcomes [Antioxidant]
(1)Diacron-Reactive Oxygen Metabolites test (Week 0, 1, 4, 8, 12)
(2)Biological Antioxidant Potential test (Week 0, 1, 4, 8, 12)
(3)Blood thiobarbituric acid reactive substances (Week 0, 1, 4, 8, 12)
(4)Urinary isoprostane (Week 0, 4, 8, 12)
(5)Urinary 8-OHdG (Week 0, 4, 8, 12)
[Safety]
(1)Blood pressure, pulsation (Week 0, 1, 4, 8, 12)
(2)Weight, body fat percentage, BMI (Week 0, 1, 4, 8, 12)
(3)Hematologic test (Week 0, 4, 8, 12)
(4)Blood biochemical test (Week 0, 4, 8, 12)
(5)Urine analysis (Week 0, 4, 8, 12)
(6)Doctor's questions (Week 0, 1, 4, 8, 12)
[Other]
(1)Subject's diary (each day during the test period)

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Individual
Blinding Double blind -all involved are blinded
Control Placebo
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Prevention
Type of intervention
Food
Interventions/Control_1 Oral ingestion of the test products containing 150mg mushroom mycelium powder (2 grains x 1 times per a day; 12 weeks)
Interventions/Control_2 Oral ingestion of the control products not containing mushroom emycelium powder (2 grains x 1 times per a day; 12 weeks)
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit
65 years-old >
Gender Male and Female
Key inclusion criteria [1]Japanese males and females aged 40-64 years
[2]Individuals who are healthy and are not received treatment of disease
[3]Individuals who feel tired by a physical labor
[4]Individuals who serve a five-day work week (from Monday to Friday) and whose working hours are over 40 hours per a week
[5]Individuals whose written informed consent has been obtained
[6]Individuals who can come to the designated venue for this study and be inspected
[7]Individuals judged appropriate for the study by the principal
Key exclusion criteria [1]Individuals using medical products
[2]Individuals who have a history of psychiatric disease, sleep disorder, high blood pressure, diabetes, and hyperlipidemia
[3]Individuals who take medicine in the past 1 month to remedy disease
[4]Individuals who have a history of serious hepatopathy, kidney damage, heart disease and hematological disease
[5]Individuals who is a patient or have a history of or endocrine disease
[6]Individuals whose BMI is over 30kg/m2
[7]Individuals who donated blood over 200mL in the past 1 month or over 400mL in the past 3 months
[8]Individuals with serious anemia
[9]Individuals who are sensitive to test product or other foods, and medical products
[10]Individuals who are or are possibly, or are lactating
[11]Individuals who excessively take alcohol (expressed in an amount of alcohol: over 60mg/day)
[12]Individuals whose life style will change during the test period (ex. a night shift, travel for a long time, job transfer)
[13]Individuals who had a habit to ingest health-promoting foods, foods for specified health uses, health foods, or supplements in the past 3 month or will ingest those foods during the test period
[14]Individuals who participated in other clinical studies in the past 3 months
[15]Individuals judged inappropriate for the study by the principal
Target sample size 64

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Mitsuhiro Sugimoto
Organization Otsubokai Medical Corporation Tohto Bunkyo Hospital
Division name Head
Zip code
Address 3-5-7 Yushima Bunkyo-ku Tokyo 113-0034, JAPAN
TEL 03-3831-2181
Email info@tes-h.co.jp

Public contact
Name of contact person
1st name
Middle name
Last name Toshiyasu Tamura
Organization TES Holdings Co., Ltd.
Division name Department of Clinical Trial
Zip code
Address 6F University of Tokyo Entrepreneur Plaza 7-3-1 Hongo Bunkyo-ku Tokyo 113-0033, JAPAN
TEL 03-6801-8480
Homepage URL
Email info@tes-h.co.jp

Sponsor
Institute RCT Japan Inc.
Institute
Department

Funding Source
Organization Golden Biotechnology Corp.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2016 Year 07 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2016 Year 06 Month 13 Day
Date of IRB
Anticipated trial start date
2016 Year 07 Month 02 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2016 Year 07 Month 01 Day
Last modified on
2017 Year 02 Month 09 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026301

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.